$835 Million is the total value of Foresite Capital Management IV, LLC's 13 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 30.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | $301,368,000 | -21.7% | 9,671,643 | 0.0% | 36.10% | -13.6% | |
| PHVS | New | Pharvaris N.V. | $91,269,000 | – | 3,261,926 | +100.0% | 10.93% | – |
| ACRS | Buy | Aclaris Therapeutics, Inc. | $85,656,000 | +1291.6% | 3,399,034 | +257.3% | 10.26% | +1433.6% |
| KROS | Sell | Keros Therapeutics, Inc. | $85,102,000 | -14.6% | 1,382,641 | -2.1% | 10.19% | -5.8% |
| RLAY | Relay Therapeutics, Inc. | $73,958,000 | -16.8% | 2,139,380 | 0.0% | 8.86% | -8.3% | |
| ALXO | Sell | ALX Oncology Holdings Inc. | $57,956,000 | -30.9% | 785,945 | -19.3% | 6.94% | -23.8% |
| KURA | Buy | Kura Oncology, Inc. | $52,298,000 | -11.4% | 1,849,947 | +2.3% | 6.26% | -2.3% |
| NRIX | Sell | Nurix Therapeutics, Inc. | $38,504,000 | -50.1% | 1,238,456 | -47.3% | 4.61% | -45.0% |
| CYTK | Sell | Cytokinetics Incorporated | $20,513,000 | -31.3% | 881,901 | -38.6% | 2.46% | -24.2% |
| OLMA | Sell | Olema Pharmaceuticals, Inc. | $13,041,000 | -66.8% | 393,030 | -52.0% | 1.56% | -63.4% |
| CBAY | Cymabay Therapeutics, Inc. | $8,113,000 | -20.9% | 1,787,094 | 0.0% | 0.97% | -12.7% | |
| RACA | Therapeutics Acquisition Corp | $3,679,000 | -24.5% | 350,000 | 0.0% | 0.44% | -16.6% | |
| DBTX | New | Decibel Therapeutics, Inc. | $3,382,000 | – | 297,711 | +100.0% | 0.40% | – |
| PCVX | Exit | Vaxcyte, Inc. | $0 | – | -465,821 | -100.0% | -1.34% | – |
| GBIO | Exit | Generation Bio Co. | $0 | – | -857,939 | -100.0% | -2.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.